Month: October 2020

55515-98-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.55515-98-5,(R)-3,3′-Dimethyl-[1,1′-binaphthalene]-2,2′-diol,as a common compound, the synthetic route is as follows.

About 23 g (0.202 mol) of potassium t-butoxide was added to a solution of 30 g (0.109 mol) of (R)-3,31-dimethyl-2,2′-dihydroxy-1,1′-dinaphthyl and 62.0 g (0.101 mol) of ditosylate of 3,6,9,12-tetraoxa-8[(allyloxy)methyl]-1,14-tetradecanediol in 8 L of t-butanol and stirred under nitrogen at 25 C. The mixture was refluxed for 72 hours, cooled, and shaken with 500 ml each of CHCl3 and H2O. The organic layer was dried and evaporated under reduced pressure. The residue was purified on silica gel by elution with hexane and ethyl acetate starting from 50:1 and moving toward solely ethyl acetate. From this, 23.18 g of (R)-[13(allyloxy)methyl]-2,3,4,5-bis[1,2-(3-methylnaphto)]-1,6,9,12,15,18-hexaoxacycloeicosa-2,4-diene was obtained.

The synthetic route of 55515-98-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; IBC Advanced Technologies, Inc.; US6686479; (2004); B2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

485-71-2,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.

Resolution of the enantiomers of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid The resolution of the enantiomers of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid was carried out via reaction with the following chiral bases: BrucineQuinine(-)-Cinchonidine(+)-CinchonineR-(+)-1-Phenylethylamine(1 R,2S)-(-)-Ephedrine hydrochloride(1S,2R)-(+)-Ephedrine hydrochloride. In each case the reactions were carried out with 0.5 and 1 equivalents of base in respect to 1 equivalent of the acid compound and by using the following solvents EthanolAcetoneAcetonitrilDioxaneEthylacetateChloroform. The results are summarized in the following tables. It may be understood that the afore mentioned crystallisation experiments that are not reflected in the following tables did not yield crystals of the respective salts under the given conditions. However, suitable conditions for crystallization of these salts can be determined by those skilled in the art via routine experiments. In the following tables Acid represents racemic 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazo)e-3-carboxylic acid R-Acid represents the respective derivative of (R)-5-( 4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acid S-Acid represents the respective derivative of (S)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-pyrazole-3-carboxylic acidProcesses for crystallisation: Process A: A solution of the chiral base was added on top of a solution of the racemic acid at room temperature.Process C: A solution of the racemic acid was added on top of a solution of the chiral base. The mixture was heated to reflux and solvent was added until dissolution was complete. The solution was left to crystallisation at r.t.Process D: The chiral base was directly added on top of a solution of the racemic acid at room temperature.Process E: The chiral base was directly added on top of a solution of the racemic acid at reflux temperature.Process F: The solution of the salt was evaporated to dryness. The residue was dissolved in a minimum amount of the solvent under reflux heating. The solution was left to crystallisation at r.t.Resolution with (-)-Cinchonidine [Show Image] Acid g (mmol) Eq. amine Proc. Solvent for crystallisation T CrystYield 1st Cryst. % % S-Acid % R-Acid0,4 g (1,09 mmol) 1 F 2ml dioxane r.t 31 94,4 5,60,4 g (1,09 mmol) 1 F 19ml Ethylacetate r.t 28,5 95,8 4,20,4 g (1,09 mmol) 1 F 20ml acetone r.t. 19,6 96,9 3,10,4 g (1,09 mmol) 1 F 24ml acetonitrile r.t 42 85,8 14,1

As the paragraph descriping shows that 485-71-2 is playing an increasingly important role.

Reference£º
Patent; Laboratorios del Dr. Esteve S.A.; EP1944293; (2008); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1662-01-7,4,7-Diphenyl-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

1662-01-7, Under an argon atmosphere, [Cu(MeCN)4]-PF6 (58 mg) was added to dppb (64 mg) in a CH2Cl2 solvent.Then, dpp (50 mg) was added. The reaction mixture was stirredfor 15 min at room temperature. Diethyl ether was added to thesolution, and kept under refrigeration. The formed solid wasfiltered, and additional diethyl ether was added to the filtrateto form yellow solid, which was filtered, washed with diethylether, and dried in vacuo: yield, 57 mg (51%). 1H NMR (500MHz, acetone-d6) 9.06 (d, 4H, J = 5 Hz, phen), 8.07 (s, 4H,phen), 7.83 (d, 4H, J = 5 Hz, phen), 7.67.3 (m, 60H, Ph), 2.21(br).21 Anal. Found: C, 64.46; H, 4.20; N, 2.75%. Calcd. for 3,C104H88N4P6F12Cu2: C, 64.56; H, 4.58; N, 2.90.

1662-01-7 4,7-Diphenyl-1,10-phenanthroline 72812, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Nishikawa, Michihiro; Kakizoe, Daichi; Saito, Yuma; Ohishi, Tomoyuki; Tsubomura, Taro; Bulletin of the Chemical Society of Japan; vol. 90; 3; (2017); p. 286 – 288;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.3779-42-8,3-Bromo-N,N,N-trimethylpropan-1-aminium bromide,as a common compound, the synthetic route is as follows.

Compound 14 (50 mg, 0.05 mmol) is dissolved and K2C03 (150 mg, 1.1 mmol) is suspended in DMF (30 mL). To the vigorously-stirred mixture a solution of (1-BROMOPROPYL)-TRIMETHYLAMMONIUM bromide (0.3 g, 16.6 mmol) in DMF (10 mL) is added dropwise at 50C and the mixture is heated for 18 h. After removal of DMF under high vacuum, the residue obtained is dissolved in methanol (5 ML) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 CM). After washing the pad with methanol (ca. 500 mL) it is eluted with acetic acid: methanol: water (3: 2: 1, by vol. ). After evaporation of solvent from appropriate combined fractions the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (5: 4: 1, by vol. , upper phase) for further separation from the excess ammonium salt and other by-products. After removal of solvent under reduced pressure the residue obtained is dissolved in methanol and passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After evaporation of solvent under reduced pressure, the product is dried under high vacuum. 1 H-NMR : sH (300MHZ, CD30D): 0.80 (t, 3J 7.5 Hz, 6 H), 1.15-1. 35 (m, 28 H), 1.35-1. 45 (bs, 4 H), 1.70-1. 80 (bs, 4 H), 2.30-2. 40 (BS, 4 H), 3.15-3. 30 (bs, 18 H), 3.65-3. 75 (bs, 4 H), 4.00-4. 05 (m, 4 H), 4.30-4. 40 (bs, 4 H), 7.00-7. 15,7. 20-7.30, 7. 80-95, 7.95-8. 15 (4 x m, 4 x 4 H), 8.60-9. 00 (bs, 8 H)., 3779-42-8

3779-42-8 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide 151145, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

135616-36-3, (S,S)-(+)-N,N’-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

8,0 g (0,015 mol) (S, S)-2, 2 – [1, 2-CYCLOHEXANDIYL) bis (nitrilomethylidyn)] bis [4,6-di- tert.-butyl)-phenol] werden in 200 ml Ethanol vorgelegt und mit 2,5 g (0,01 mol) Vanadylsulfat-Pentahydrat versetzt. Nach zwei Stunden unter Rueckfluss wird das Loesungsmittel abdestilliert, der Rueckstand in 400 ML Dichlormethan aufgenommen und die Loesung mit 200 ml Wasser gewaschen. Nach Phasentrennung, Trocknen der Loesung mit Natriumsulfat und Abdestillieren des Loesungsmittels erhaelt man 8,2 g gruenes, amorphes Pulver. Zusammensetzung des Gemischs nach HPLC (Gew. -%) : Komponente (I) : (X) : (III) =85% : 15% : 0%. [alpha D20 = +200 (c = 0,01, Chloroform)., 135616-36-3

As the paragraph descriping shows that 135616-36-3 is playing an increasingly important role.

Reference£º
Patent; CLARIANT GMBH; WO2004/55028; (2004); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.54761-04-5,Ytterbium(III) trifluoromethanesulfonate,as a common compound, the synthetic route is as follows.

Under the protection of nitrogen atmosphere, the amount of organic solvent (for the volume ratio of 1: 0.2 of a mixture of polyethylene glycol and 15-crown-5) was added 100 mmol of the compound of formula (I) 250 mmol of the compound of formula (II) above, 9 mmol of catalyst (3 mmol Pd(dba)2) With 6mmol A mixture of ytterbium trifluoromethanesulfonate ,12 mmol oxidizer silver acetate and 30 mmol accelerator N-n-butyl-N-methylpiperidine bis(trifluoromethanesulfonyl)imide salt, and then the temperature was raised to 70 C, and the reaction was stirred at that temperature for 6 hours. After the reaction is complete, the filtrate is adjusted to adjust the pH of the filtrate to neutral and then saturated with hydrogen carbonate Sodium aqueous solution is fully shaken washing, adding dichloromethane extraction, separation of organic phase, and then Dried over anhydrous sodium sulfate, concentrated under reduced pressure, the residue over 200-300 mesh silica gel column chromatography, in vivo A mixture of petroleum ether and acetone having a ratio of 1: 3 was used as the eluent to give a compound of formula (III) And the yield was 93.9%., 54761-04-5

The synthetic route of 54761-04-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Henan Academy Of Sciences Chemical Institute Co., Ltd.; Huo Cuimeng; Fu Yang; Chen Jin; Zhang Xin; Zhao Yongde; (9 pag.)CN105037081; (2016); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

62937-45-5, Example 53(fi)-1 -[5-(4-{(S)-1 -[(S)-6-(2-Hvdroxy-2-methyl-DroDyl)-2-oxo-6-Dhenyl-[1 .3loxazinan-3-yll- ethyl)-phenyl)-pyridin-2-yl1-pyrrolidine-2-carboxylic acid amide; A mixture of 3-{(S)-1 -[4-(6-fluoro-pyridin-3-yl)-phenyl]-ethyl}-(S)-6-(2-hydroxy-2-methyl- propyl)-6-phenyl-[1 ,3]oxazinan-2-one (165 mg), potassium carbonate (76 mg), D-prolinamide (125 mg), and dimethyl sulfoxide (2 ml_) was stirred at 100 ‘ overnight. After cooling to room temperature, aqueous NaHC03 solution was added and the resulting mixture was extracted with dichloromethane. The combined extracts were concentrated and the residue was purified by HPLC on reversed phase (water/methanol) to give the title compound. Yield: 85 mg (43% of theory); Mass spectrum (ESI+): m/z = 543 [M+H]+.

The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; VITAE PHARMACEUTICALS, INC.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; LEFTHERIS, Katerina; ZHUANG, Linghang; TICE, Colin, M.; SINGH, Suresh, B.; YE, Yuanjie; XU, Zhenrong; HIMMELSBACH, Frank; ECKHARDT, Matthias; WO2011/159760; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.

solution of DOTA tri-t-butyl ester (0.972 g, 1.70 mmol), HBTU (0.772 g, 2.04 mmol), HOBt (0.312 g, 2.04 mmol), and DIEA (0.59 niL, 5.9 mmol) in anhydrous DMF (8.0 mL) was stirred at room temperature under nitrogen for 20 minutes. The product of Part B (1.38 g, 1.70 mmol) was added in one portion. Additional HBTU (0.772 g, 2.04 mmol) was added after 1 hour and the reaction was stirred for an additional 3 hours. The reaction mixture was quenched with 10% citric acid (20 mL) and diluted with dichloromethane (30 mL). The aqueous layer was extracted with dichloromethane (3 x 30 mL). The combined organic extracts were washed consecutively with 10% citric acid (30 mL), saturated NaHCO3 (3 x 30 mL), and saturated NaCl (3 x 30 mL), dried (MgSO4), filtered, and concentrated to give a yellow oil. The oil was purified by flash chromatography over silica gel, eluting with ethyl acetate to give the title compound as a colorless oil (0.746 g, 48%). 1H NMR (4:1 CDCl3:DMSO-<4): delta 7.54 (m, 2H), 7.41 (m, 2H), 7.17 (m, 2H), 7.08 (m, 2H), 4.15 (d, 2H), 4.02 (m, IH), 2.97 (m, 2H), 2.68-2.45 (m, 24H), 2.00 (t, 2H), 1.44 (t, 2H), 1.30-1.11 (m, 31H). MS (ESI): 461.9 (100, M+2H), 922.5 (80, M+H)., 137076-54-1

As the paragraph descriping shows that 137076-54-1 is playing an increasingly important role.

Reference£º
Patent; BRISTOL-MYERS SQUIBB PHARMA COMPANY; WO2007/5491; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

103505-54-0, [2,2′-Bipyridine]-6,6′(1H,1’H)-dione is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

As shown in Synthesis Scheme 1-a, to a dicationic Cp * iridium-aco complex (407.8 mg, 0.60 mmol) was added 6,6′-dihydroxy-2,2′-bipyridine ligand (113.8 mg, 0 , 60 mmol) was allowed to act in an aqueous solvent (12 mL) to obtain a complex A (yield 93%). Subsequently, neutral iridium complex 1 was obtained by allowing sodium t-butoxide (211.4 mg, 2.2 mmol) to react with complex A (915.0 mg, 1.1 mmol) in an aqueous solvent (30 mL) (Yield 84%)., 103505-54-0

The synthetic route of 103505-54-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; KANTO CHEM CO INC; YAMAGUCHI, RYOHEI; FUJITA, KENICHI; (38 pag.)JP2015/83544; (2015); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 7: 1-r(3-(6-Methyl-4-r(3.3.3-trifluoro-2-m(4-fluorophenvnsulfonylU1- methylethv?aminolmethyl’y-2-hvdroxypropy?aminol-1/-/-indazol-1-yl)phenv?carbonyl1- D-prolinamide; lambda/,lambda/-Diisopropylethylamine (0.0644mL) and HATU (29.5mg) were added to a solution of 3-(4-{[2-({ethyl[(4-fluorophenyl)sulfonyl]amino}methyl)-3,3,3-trifluoro-2- hydroxypropyl]amino}-6-methyl-1/-/-indazol-1-yl)benzoic acid (45mg, 0.074mmol) in DMF (1.4mL) and the mixture stirred at room temperature under for 10 min. D- Prolinamide (21.1 mg) was then added and the mixture stirred at room temperature overnight. More D-prolinamide was added and the mixture stirred for a further 24 hours and then diluted slightly with methanol and purified by mass directed autopreparation (System B). Product containing fractions were combined and partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The aqueous phase was re-extracted with dichloromethane and the combined organic extracts were washed successively with water and brine, dried through a hydrophobic frit and evaporated to give the title compound (22.2mg). LCMS: tRET = 3.38 min; MH+ = 70519mg of this mixture of diastereomers was resolved by chiral HPLC on a 2 x 25cm Chiralpak AD column eluted with heptane : iso-propanol 1 : 1 with a flow rate of 15 mL/min to provide Example 7-A (diastereomer A, 6.5mg) and Example 7-B (diastereomer B, 7.5mg).Example 7-A (diastereomer A): Analytical chiral HPLC (25 x 0.46 cm Chiralpak AD column, heptane : iso-propanol 1 : 1 eluting at 1 mL/min): tREtau = 8.6 min LCMS: tRET = 3.41 min; MH+ = 705Example 7-B (diastereomer B): Analytical chiral HPLC (25 x 0.46 cm Chiralpak AD column, heptane : iso-propanol 1 : 1 eluting at 1 mL/min): tREtau = 11.6 min LCMS: tRET = 3.59 min; MH+ = 705, 62937-45-5

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2009/50218; (2009); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI